Medizinisches Versorgungszentrum Am Bahnhof Spandau GbR
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Medizinisches Versorgungszentrum Am Bahnhof Spandau GbR researchers are focused on reducing the burden of heart failure and related cardiovascular events, especially in patients who also carry excess weight. Recent studies explore whether adding new agents to standard therapy can lower the risk of cardiovascular death, hospitalisation for heart failure, and major adverse cardiac events. The site also evaluates innovative treatments aimed at improving outcomes for individuals with HFpEF or HFmrEF combined with obesity.
- Combination of a novel mineralocorticoid antagonist with dapagliflozin to prevent heart‑failure events
- Impact of NNC0487-0111 on hospitalisation rates for heart failure in obese patients
- Comparison of tirzepatide versus dulaglutide for major cardiovascular outcomes in high‑risk diabetes
- Assessment of cardiovascular safety in participants with mixed heart‑failure phenotypes
These investigations aim to expand therapeutic options for people at risk of heart failure, highlighting the site’s commitment to advancing cardiovascular care.
Nutritional and Metabolic Diseases
The clinic’s metabolic research program addresses both weight management and diabetes control. Trials evaluate the effectiveness of weekly injectable therapies for achieving sustained weight loss and for improving glycaemic metrics in type 1 diabetes and type 2 diabetes populations. By testing novel glucagon‑like peptide‑1 (GLP‑1) analogues and once‑weekly insulin formulations, the site seeks to simplify treatment regimens while maintaining or enhancing blood‑sugar control.
- Efficacy of cafraglutide for chronic weight management in overweight adults
- Non‑inferiority of once‑weekly insulin icodec compared with daily basal insulins in type 1 diabetes
- Real‑world effectiveness of weekly insulin icodec for intensifying therapy in type 2 diabetes
- Assessment of metabolic benefits when combining GLP‑1 therapy with standard diabetes care
Through these studies, the site contributes to better strategies for obesity and diabetes, aiming to improve patients’ quality of life and long‑term health outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 24 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1AstraZeneca AB4active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB4trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medizinisches Versorgungszentrum Am Bahnhof Spandau GbR
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 4, Randomized, Open-Label, Active-Controlled Study to Investigate the Efficacy and Safety of Switching From Weekly Dulaglutide to Weekly Tirzepatide in Adults With Type 2 Diabetes | Eli Lilly Cork Limited | Phase III | Not Yet Recruiting | Jun 2023 | Jul 2024 |
IMP list
lock Showing 1 of 24 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 4 | Unknown | 2023-06-07 | 2025-05-06 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.